1 | primary | 74,593 |
2 | primary/secondary | 13 |
3 | assent-4 | 9 |
4 | heparin-mediated | 5 |
5 | neurothera® | 5 |
6 | months.primary | 4 |
7 | stent-oriented | 4 |
8 | misaho | 3 |
9 | dpp/diabetes | 2 |
10 | low-hc | 2 |
11 | low-metastasizing | 2 |
12 | nonidet | 2 |
13 | primary-medical | 2 |
14 | prognosis.the | 2 |
15 | quseir | 2 |
16 | rwth | 2 |
17 | strauss-carpenter | 2 |
18 | usual.primary | 2 |
19 | 'await | 1 |
20 | 'osteoporosis | 1 |
21 | 'super-mini | 1 |
22 | .oh-removing | 1 |
23 | 2.82+/-0.62 | 1 |
24 | 8-of-64 | 1 |
25 | 82,120 | 1 |
26 | adult-offspring | 1 |
27 | all-cause-safety | 1 |
28 | amh-primary | 1 |
29 | animial | 1 |
30 | anti-erosive/anti-abrasive | 1 |
31 | antifall | 1 |
32 | between-race | 1 |
33 | bh3-mimetic | 1 |
34 | biomarker-surrogate | 1 |
35 | biomarker-surrogate-clinical | 1 |
36 | chemo-antiangiogenic | 1 |
37 | clinical/microbiological | 1 |
38 | cost.the | 1 |
39 | co–primary | 1 |
40 | de-pigmenting | 1 |
41 | diagnosis-based | 1 |
42 | dose.immunogenicity | 1 |
43 | ducth | 1 |
44 | elderly.the | 1 |
45 | endometrial-confined | 1 |
46 | extubation/successful | 1 |
47 | fact-trial | 1 |
48 | fmri-activated | 1 |
49 | forward-shift | 1 |
50 | goal-conducive | 1 |
51 | gy.primary | 1 |
52 | high-hc | 1 |
53 | high-numerical-aperture | 1 |
54 | hours.primary | 1 |
55 | hsv-sr39tk/gcv-induced | 1 |
56 | in-tumor | 1 |
57 | inph-specific | 1 |
58 | ira-only | 1 |
59 | job.the | 1 |
60 | language-treatment | 1 |
61 | larynx-hypopharynx | 1 |
62 | lipoprotein-altering | 1 |
63 | mclean-harvard-international | 1 |
64 | melanoma-derived | 1 |
65 | ms/mri | 1 |
66 | neurological/functional | 1 |
67 | non-pcr-corrected | 1 |
68 | nonatherothrombotic | 1 |
69 | operation.the | 1 |
70 | overally | 1 |
71 | pip3-removing | 1 |
72 | predictcing | 1 |
73 | randomisationsecondary | 1 |
74 | randomization.primary | 1 |
75 | recurrence-preventing | 1 |
76 | sapphire-like | 1 |
77 | seizure-prevention | 1 |
78 | short-/middle-term | 1 |
79 | tobacco-colorectal | 1 |
80 | tractocile | 1 |
81 | tsc1/2 | 1 |
82 | usphs/idsa | 1 |
83 | yale-griffin | 1 |
1 | 'await | 1 |
2 | 'osteoporosis | 1 |
3 | 'super-mini | 1 |
4 | .oh-removing | 1 |
5 | 2.82+/-0.62 | 1 |
6 | 8-of-64 | 1 |
7 | 82,120 | 1 |
8 | adult-offspring | 1 |
9 | all-cause-safety | 1 |
10 | amh-primary | 1 |
11 | animial | 1 |
12 | anti-erosive/anti-abrasive | 1 |
13 | antifall | 1 |
14 | assent-4 | 9 |
15 | between-race | 1 |
16 | bh3-mimetic | 1 |
17 | biomarker-surrogate | 1 |
18 | biomarker-surrogate-clinical | 1 |
19 | chemo-antiangiogenic | 1 |
20 | clinical/microbiological | 1 |
21 | cost.the | 1 |
22 | co–primary | 1 |
23 | de-pigmenting | 1 |
24 | diagnosis-based | 1 |
25 | dose.immunogenicity | 1 |
26 | dpp/diabetes | 2 |
27 | ducth | 1 |
28 | elderly.the | 1 |
29 | endometrial-confined | 1 |
30 | extubation/successful | 1 |
31 | fact-trial | 1 |
32 | fmri-activated | 1 |
33 | forward-shift | 1 |
34 | goal-conducive | 1 |
35 | gy.primary | 1 |
36 | heparin-mediated | 5 |
37 | high-hc | 1 |
38 | high-numerical-aperture | 1 |
39 | hours.primary | 1 |
40 | hsv-sr39tk/gcv-induced | 1 |
41 | in-tumor | 1 |
42 | inph-specific | 1 |
43 | ira-only | 1 |
44 | job.the | 1 |
45 | language-treatment | 1 |
46 | larynx-hypopharynx | 1 |
47 | lipoprotein-altering | 1 |
48 | low-hc | 2 |
49 | low-metastasizing | 2 |
50 | mclean-harvard-international | 1 |
51 | melanoma-derived | 1 |
52 | misaho | 3 |
53 | months.primary | 4 |
54 | ms/mri | 1 |
55 | neurological/functional | 1 |
56 | neurothera® | 5 |
57 | non-pcr-corrected | 1 |
58 | nonatherothrombotic | 1 |
59 | nonidet | 2 |
60 | operation.the | 1 |
61 | overally | 1 |
62 | pip3-removing | 1 |
63 | predictcing | 1 |
64 | primary | 74,593 |
65 | primary-medical | 2 |
66 | primary/secondary | 13 |
67 | prognosis.the | 2 |
68 | quseir | 2 |
69 | randomisationsecondary | 1 |
70 | randomization.primary | 1 |
71 | recurrence-preventing | 1 |
72 | rwth | 2 |
73 | sapphire-like | 1 |
74 | seizure-prevention | 1 |
75 | short-/middle-term | 1 |
76 | stent-oriented | 4 |
77 | strauss-carpenter | 2 |
78 | tobacco-colorectal | 1 |
79 | tractocile | 1 |
80 | tsc1/2 | 1 |
81 | usphs/idsa | 1 |
82 | usual.primary | 2 |
83 | yale-griffin | 1 |
1 | 82,120 | 1 |
2 | tsc1/2 | 1 |
3 | 2.82+/-0.62 | 1 |
4 | assent-4 | 9 |
5 | 8-of-64 | 1 |
6 | usphs/idsa | 1 |
7 | high-hc | 1 |
8 | low-hc | 2 |
9 | inph-specific | 1 |
10 | chemo-antiangiogenic | 1 |
11 | bh3-mimetic | 1 |
12 | nonatherothrombotic | 1 |
13 | hsv-sr39tk/gcv-induced | 1 |
14 | endometrial-confined | 1 |
15 | diagnosis-based | 1 |
16 | heparin-mediated | 5 |
17 | fmri-activated | 1 |
18 | non-pcr-corrected | 1 |
19 | stent-oriented | 4 |
20 | melanoma-derived | 1 |
21 | between-race | 1 |
22 | job.the | 1 |
23 | operation.the | 1 |
24 | prognosis.the | 2 |
25 | cost.the | 1 |
26 | elderly.the | 1 |
27 | sapphire-like | 1 |
28 | tractocile | 1 |
29 | high-numerical-aperture | 1 |
30 | biomarker-surrogate | 1 |
31 | goal-conducive | 1 |
32 | anti-erosive/anti-abrasive | 1 |
33 | predictcing | 1 |
34 | lipoprotein-altering | 1 |
35 | adult-offspring | 1 |
36 | de-pigmenting | 1 |
37 | recurrence-preventing | 1 |
38 | pip3-removing | 1 |
39 | .oh-removing | 1 |
40 | low-metastasizing | 2 |
41 | ducth | 1 |
42 | rwth | 2 |
43 | 'super-mini | 1 |
44 | ms/mri | 1 |
45 | primary-medical | 2 |
46 | clinical/microbiological | 1 |
47 | biomarker-surrogate-clinical | 1 |
48 | animial | 1 |
49 | fact-trial | 1 |
50 | mclean-harvard-international | 1 |
51 | neurological/functional | 1 |
52 | tobacco-colorectal | 1 |
53 | antifall | 1 |
54 | extubation/successful | 1 |
55 | short-/middle-term | 1 |
56 | yale-griffin | 1 |
57 | seizure-prevention | 1 |
58 | misaho | 3 |
59 | strauss-carpenter | 2 |
60 | quseir | 2 |
61 | in-tumor | 1 |
62 | dpp/diabetes | 2 |
63 | 'osteoporosis | 1 |
64 | nonidet | 2 |
65 | forward-shift | 1 |
66 | 'await | 1 |
67 | language-treatment | 1 |
68 | larynx-hypopharynx | 1 |
69 | overally | 1 |
70 | ira-only | 1 |
71 | primary/secondary | 13 |
72 | randomisationsecondary | 1 |
73 | primary | 74,593 |
74 | amh-primary | 1 |
75 | usual.primary | 2 |
76 | randomization.primary | 1 |
77 | months.primary | 4 |
78 | hours.primary | 1 |
79 | gy.primary | 1 |
80 | co–primary | 1 |
81 | all-cause-safety | 1 |
82 | dose.immunogenicity | 1 |
83 | neurothera® | 5 |